Role of transforming growth factor beta 1 in induction of colon carcinoma differentiation by hexamethylene bisacetamide

Cancer Res. 1990 Jan 15;50(2):261-5.

Abstract

The differentiation agent hexamethylene bisacetamide (HMBA) increased expression of transforming growth factor beta 1 (TGF beta 1) mRNA in HT29 colon carcinoma cells. The increase was evident after 24 h and was maintained at levels 4-5-fold the control levels for at least 5-13 days. No increase in expression of TGF beta 2 or TGF alpha mRNA was observed. Both TGF beta 1 and HMBA induced loss of expression of a cell surface malignancy marker on HT29 cells, and both decreased cell growth in serum-free medium. Exogenously applied TGF beta 1 mimicked the growth-arresting effect of HMBA on three surgically resected moderately differentiated colon carcinomas in serum-free primary culture. Both TGF beta 1 and HMBA increased the tumor growth fraction in a second group of three more aggressive colon carcinomas, while neither agent had any measurable growth-modulating activity on two other colon carcinomas. The induction of TGF beta 1 mRNA by HMBA along with the parallel biological effects of HMBA and exogenously applied TGF beta 1 on resected carcinomas and on HT29 cells suggest that the effects of HMBA on colon carcinoma cells may be mediated in part by induction of TGF beta 1.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Acetamides / pharmacology*
  • Biomarkers, Tumor / analysis
  • Carcinoma / pathology*
  • Cell Differentiation / drug effects
  • Colonic Neoplasms / pathology*
  • Humans
  • RNA, Messenger / biosynthesis
  • Transforming Growth Factors / genetics
  • Transforming Growth Factors / pharmacology*
  • Tumor Cells, Cultured

Substances

  • Acetamides
  • Biomarkers, Tumor
  • RNA, Messenger
  • Transforming Growth Factors
  • hexamethylene bisacetamide